PolarityTE Builds Patent Portfolio with New International Patent Grants

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that the company has recently been granted a patent in New Zealand and has received approvals for patent applications in the United Kingdom and Australia. The grant of PolarityTE’s Canadian patent was announced in August, bringing the total number of patents and approvals in 2019 to four. These developments demonstrate the momentum of PolarityTE’s ongoing efforts to develop, support and protect its intellectual property.

The New Zealand patent and the UK and Australian patent acceptances relate to PolarityTE’s distinctive micro-aggregate technology. Aspects of this micro-aggregate technology are central to the Company’s SkinTE product, which is commercially available in the United States for the repair, replacement, reconstruction or supplementation of skin tissue in wound, trauma and burn patients.

“These additional approvals demonstrate the advancement of our patent procurement efforts and the value of our tissue regeneration technology,” said Jennifer Burdman, Chief Intellectual Property Officer at PolarityTE. “The patent grants we’ve obtained this year demonstrate the ongoing success of our strategy to build out PolarityTE’s IP portfolio. We value the impressive innovation of the PolarityTE team and will continue to invest in the protection of these important assets.”

The New Zealand patent was granted as number 733433 on December 5, 2019. The applications that have been approved and will soon be issued as granted patents are United Kingdom Patent Application No. GB1902819.0 and Australian Patent Application No. 2015355187. PolarityTE continues to pursue patent protection related to its micro-aggregate technology in the United States and internationally. Additional technologies invented by the Company are being pursued in patent applications in the U.S. and abroad.

PolarityTE President David Seaburg added, “We are pleased to see that our intellectual property portfolio continues to gain strength. Validating our innovative technology is part of our ongoing commitment to change the lives of patients with our current SkinTE product and the other products that are part of our pipeline.”

About PolarityTE

PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates a dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift.